Search company, investor...

TheraGenetics

theragenetics.com

Founded Year

2006

Stage

Other Investors | Alive

About TheraGenetics

theraGenetics is a personalized medicine diagnostics company developing pharmacogenetic tests to guide and improve the treatment of central nervous system (CNS) disorders; matching the medication to the patient.

Headquarters Location

King's College London Institute of Psychiatry P.O 51, De Crespigny Park, Denmark Hill

SE5 8AF,

United Kingdom

Missing: TheraGenetics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: TheraGenetics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

TheraGenetics Frequently Asked Questions (FAQ)

  • When was TheraGenetics founded?

    TheraGenetics was founded in 2006.

  • What is TheraGenetics's latest funding round?

    TheraGenetics's latest funding round is Other Investors.

  • Who are the investors of TheraGenetics?

    Investors of TheraGenetics include Tudor Ventures, Swarraton Partners, Javelin Venture Partners, IP Group, Top Technology Ventures and 3 more.

  • Who are TheraGenetics's competitors?

    Competitors of TheraGenetics include Decipher Biosciences, Upromise, Foundation Medicine, Advanced Cell Diagnostics, CyVek and 12 more.

Compare TheraGenetics to Competitors

N
NeoDiagnostix

NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.

G
G-Nostics

G-Nostics is a company in the field of personalised medicine based on the science of pharmacogenetics. The initial product is a diagnostic test, the NicoTest, focused on targeting treatment to aid smoking cessation.

P
Prognomix

Predict to Prevent Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development of presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention

G
Glycominds

Glycominds Ltd. holds knowledge and experience in the field of glycomics, utilized for the discovery and development of glycan biomarkers which enable high-value medical diagnostics. Glycominds is developing and commercializing a new class of blood tests which allow physicians to detect cancer earlier, predict autoimmune disease progression and decide on therapy regimen.

L
LifeLineLab S.r.l.

Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.